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We have read with profound interest the article by Bastos
and colleagues entitled Histologic Analysis of Zafirlukast’s
Effect on Capsule Formation Around Silicone Implants.
We have truly enjoyed this study because it focuses on the
very important issue of ongoing research toward pharma-
cologic therapy for the treatment of periprosthetic capsule
contracture. The latter has an incidence in the range of
0.5% to 50% [3]. Despite persistent clinical and laboratory
investigation, to date, no solution has been developed to
solve or prevent this problem.
For several years, many investigators have evaluated the
use of antileukotriene drugs, which could be effective in
the treatment of periprosthetic capsule contracture.
Unfortunately, their use still is not evidence based and has
no biochemical or biomolecular support. At the same time,
the use of drugs with no specific indication is strongly
criticized and discouraged for moral, medical, and legal
reasons [6].
Investigations into a molecular basis to justify the use of
CysLT antagonists have evaluated the potential modifica-
tion of cysLTR expression in human contracted capsules
[2]. The conclusions of the study by Bastos and colleagues
are supported by several clinical studies, which are
reviewed in their studies. However, the authors failed to
review the animal models proposed to date (rabbits, pigs,
rats). Although these animal studies are very accurate, they
have disadvantages in terms of reproducibility, standardi-
zation, and of course translation to the human setting [1, 4,
5, 7].
In all the experiments, the authors tried to induce con-
tracture through different methods (bacterial contamination,
fibrin glue), stressing the fundamental cellular and bio-
chemical difference between the contracted capsule and the
physiologic periprosthetic capsule. Unfortunately, Bastos
and colleagues used an animal model that, in our opinion, is
not accurate with respect to a contracted capsule. Indeed,
the authors did not induce capsular contracture in their
animal model. With the fundamental differences between
contracted and uncontracted capsules in mind, the immu-
nohistochemical and histopathology analysis was carried
out on periprosthetic physiologic capsules. Thus, the
reduced presence of inflammatory cells and the reduced
vascular density in the experimental groups (explained by
the intrinsic antiinflammatory activity of zafirlukast) cannot
definitely be proof of a therapeutic effect of the drug in
reducing or preventing capsular contracture. Moreover, it is
unclear why the authors decided to remove the prostheses
90 days after the implantation to analyze the capsules,
assuming them to be contracted.
Despite these criticisms, we thank Bastos and colleagues
for focusing their attention on a very serious problem in
plastic surgery and for proposing a histologic and immu-
nohistochemical analysis of the development of capsular
contraction. We hope that many other investigators will
undertake the same approach in fighting against this frus-
trating problem that afflicts patients, plastic surgeons, and
manufacturers.
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